Lung Cancer Dispatch
4.5K views | +0 today
Follow
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Suggested by Cancer Commons
Scoop.it!

New Clinical Trial Examines Lung Cancer Drug Bavituximab

New Clinical Trial Examines Lung Cancer Drug Bavituximab | Lung Cancer Dispatch | Scoop.it

The makers of the cancer drug bavituximab are initiating the SUNRISE trial, a phase III clinical trial investigating the efficacy of the drug against non-small cell lung cancer (NSCLC). Patients with advanced non-squamous NSCLC whose cancer has progressed after first-line treatment will receive either bavituximab plus docetaxel (Taxotere) or Taxotere by itself. Bavituximab inhibits phosphatidylserine, a protein found on the surface of tumors and tumor-associated cells that acts to suppress the body’s immune reponse. By blocking phosphatidylserine’s action, bavituximab allows the immune system to continue attacking the cancer. To find out more, patients can go to www.sunrisetrial.com.

Cancer Commons's insight:

Yahoo! Finance  |  Dec 30, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Lung Cancer Drug Bavituximab May Move Forward into Phase III Trial

Despite problems with vial labeling that weakened the findings of a recent phase II clinical trial, Peregrine Pharmaceuticals plans to move its new cancer drug bavituximab forward into a phase III trial. A second analysis of the phase II results, which adjusted for the labeling inconsistencies, still found that adding bavituximab to chemotherapy as a second-line treatment for non-small cell lung cancer (NSCLC) increased patients’ survival time, even though the difference may merely be due to chance. Bavituximab targets phosphatidylserine, a protein found on the surface of tumor blood vessels that suppresses the body’s immune response. By blocking phosphatidylserine, bavituximab allows the immune system to attack the cancer.

Cancer Commons's insight:

Cancer Network | Mar 2, 2013

more...
No comment yet.